Latanoprost + Timolol Genoptim (Timolol Maleate, Latanoprost)

The drug combines two mechanisms: Latanoprost, a prostaglandin analogue, enhances the outflow of aqueous humor through the uveoscleral pathway, while Timolol, a non‑selective beta‑blocker, reduces aqueous humor production by blocking beta‑adrenergic receptors in the ciliary body. Together they provide a greater reduction in intra‑ocular pressure than either agent alone.

The prescribed dosing regimen for Latanoprost + Timolol Genoptim is determined by the treating ophthalmologist based on the patient’s condition, response, and tolerance. Typically, one drop is instilled in the affected eye(s) once daily, but the exact schedule should follow the prescriber’s instructions.

Safety data for use during pregnancy or lactation are limited. The medication should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives and risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. After verification, the team provides pricing, availability, shipping details, and necessary import documentation.

When used alone, Latanoprost primarily increases aqueous outflow, and Timolol mainly reduces aqueous production. The combination offers a complementary effect, achieving a larger and more consistent reduction in intra‑ocular pressure, which can be advantageous for patients who need greater pressure control or who have an inadequate response to monotherapy.

The eye‑drop solution should be stored at room temperature, below 25 °C, in its original container. Protect the product from direct sunlight, excessive heat, and moisture. Keep the bottle tightly closed when not in use to maintain sterility.

The medication is applied as an ophthalmic solution. The patient should wash their hands, tilt the head back, pull down the lower eyelid to form a pocket, and place one drop into the conjunctival sac of the affected eye(s). Close the eye gently for a few seconds and avoid blinking excessively. Do not touch the dropper tip to any surface.

Serious risks include severe allergic reactions, paradoxical increase in intra‑ocular pressure, systemic beta‑blocker effects such as bradycardia, hypotension, or bronchospasm, and significant eye pain or vision loss. Patients should seek immediate medical attention if they experience any of these symptoms.

The combination should be avoided in patients with known hypersensitivity to timolol, latanoprost, or any excipients, those with severe asthma or chronic obstructive pulmonary disease, individuals with significant cardiac conduction disorders, and patients with active ocular infections or inflammation unless directed by a specialist.